NSC 319990 | 200348-82-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: NSC 319990
• 英文别名: NSC319990；1,1'-(4-METHYL-1,3-PHENYLENE)BIS(3-(2-BENZOTHIAZOLYL)UREA)；1-(1,3-Benzothiazol-2-yl)-3-[3-(1,3-benzothiazol-2-ylcarbamoylamino)-4-methylphenyl]urea
• CAS: 200348-82-9
• 化学式: C₂₃H₁₈N₆O₂S₂
• 分子量: 474.567
• InChiKey: QKNYSSVEILCLBD-UHFFFAOYSA-N

物化性质

• 密度：
  1.580±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  165
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  zinc(II) nitrate 、 NSC 319990 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  A highly selective fluorescent ‘turn-on’ chemosensor for Zn²⁺based on a benzothiazole conjugate: their applicability in live cell imaging and use of the resultant complex as a secondary sensor of CN⁻

  摘要：

  已合成一种苯并噻唑衍生物连接“开-关”多响应和选择性化学传感器<3>。

  DOI：

  10.1039/c4dt03247k
• 作为产物：
  描述：

  2-氨基苯并噻唑 、 甲苯-2,4-二异氰酸酯 以 丙酮 为溶剂， 反应 4.0h， 以82%的产率得到NSC 319990
  参考文献：
  名称：

  A highly selective fluorescent ‘turn-on’ chemosensor for Zn²⁺based on a benzothiazole conjugate: their applicability in live cell imaging and use of the resultant complex as a secondary sensor of CN⁻

  摘要：

  已合成一种苯并噻唑衍生物连接“开-关”多响应和选择性化学传感器<3>。

  DOI：

  10.1039/c4dt03247k

文献信息

• Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
  申请人：——

  公开号：US20030185793A1

  公开（公告）日：2003-10-02

  The invention relates to transport molecule binding ligand compounds which comprise a therapeutically and/or diagnostically active substance and a carrier molecule-affine substance with a high association constant to the carrier molecule. The invention also relates to medicaments containing these ligand compounds and to diagnostic kits.

  这项发明涉及与载体分子结合的配体化合物，其包括具有治疗和/或诊断活性物质以及与载体分子具有高结合常数的载体分子亲和物质。该发明还涉及含有这些配体化合物的药物和诊断试剂盒。
• COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Universidad Andres Bello

  公开号：EP2897632A2

  公开（公告）日：2015-07-29
• USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Universidad Andres Bello

  公开号：US20150337018A1

  公开（公告）日：2015-11-26

  The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention. Examples are shown for connexin 43, connexin 30 and pannexin 1 hemichannel modulators shown not to affect gap junctions, in the form of both non peptide compounds and peptides which were tested in different models for psychiatric disorders, comprising PTSD, memory, anxiety and depression.
• US7902144B2
  申请人：——

  公开号：US7902144B2

  公开（公告）日：2011-03-08
• [EN] USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS<br/>[FR] UTILISATION DE COMPOSÉS QUI MODULENT SÉLECTIVEMENT LA LIBÉRATION ASTROCYTAIRE DE SUBSTANCES PAR LES HÉMICANAUX DE CONNEXINE ET DE PANNEXINE, SANS INFLUENCER LES JONCTIONS COMMUNICANTES, POUR LE TRAITEMENT DES TROUBLES PSYCHIATRIQUES
  申请人：UNIV ANDRES BELLO

  公开号：WO2013179264A2

  公开（公告）日：2013-12-05

  The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention. Examples are shown for connexin 43, connexin 30 and pannexin 1 hemichannel modulators shown not to affect gap junctions, in the form of both non peptide compounds and peptides which were tested in different models for psychiatric disorders, comprising PTSD, memory, anxiety and depression.